IP Library Patent Application 18599623
Patent Application
App. No. 18/599,623

DEUTERATED INFIGRATINIB COMPOUNDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/599,623
Abstract

Provided herein are compounds, or salts (e.g., pharmaceutically acceptable salts), esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, which compounds comprise one or more deuterium atoms, as well as pharmaceutically compositions comprising the same. Also provided herein are methods of using the same in the treatment of various diseases, disorders, and conditions including cancers and skeletal dysplasias.

Claims (10)

1 . A compound according to Formula I:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein:

each X 1 is selected from hydrogen and deuterium, and each X 1 is the same;

each X 2 is selected from hydrogen and deuterium, and each X 2 is the same;

each X 3 is selected from hydrogen and deuterium, and each X 3 is the same;

each X 4 is selected from hydrogen and deuterium, and each X 4 is the same;

each X 5 is selected from hydrogen and deuterium, and each X 5 is the same; and

each X 6 is selected from hydrogen and deuterium, and each X 6 is the same,

provided that at least one X 1 , X 2 , X 3 , X 4 , X 5 , or X 6 is deuterium.

2 .- 94 . (canceled)

Assignments (2)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL Recorded Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.; NAVIRE PHARMA, INC.; CANTERO THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; FERRO THERAPEUTICS, INC.; BRIDGEBIO SERVICES INC.
Reel/Frame 070551/0120 →
SECURITY INTEREST Recorded Jun 28, 2024
From: BRIDGEBIO PHARMA, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.; NAVIRE PHARMA, INC.; FERRO THERAPUETICS, INC.; QED THERAPEUTICS, INC.; BRIDGEBIO GENE THERAPY RESEARCH, INC.; BRIDGEBIO SERVICES INC.; CANTERO THERAPEUTICS, INC.
To: BLUE OWL CAPITAL CORPORATION
Reel/Frame 067870/0874 →